Denali Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Denali Therapeutics Inc. (DNLI) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $22.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Denali Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $22.91M, a 10.23% decline year-over-year.
- Denali Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $23.09M, a 8.96% decline year-over-year.
- Denali Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $24.06M, a 4.89% decline year-over-year.
- Denali Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $25.30M, a 1.24% increase year-over-year.
- Denali Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $100.25M, a 3.13% decline from fiscal 2024.
- Denali Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $103.48M, a 4.53% decline from fiscal 2023.
- Denali Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $108.40M, a 8.57% increase from fiscal 2022.
- Denali Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $99.85M, a 17.13% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.91M 10-Q · filed 2026-08-06 | $46.00M 10-Q · filed 2026-08-06 | $70.06M derived: sum of 3 quarters · filed 2026-08-06 | $95.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $23.09M 10-Q · filed 2026-05-07 | $47.15M derived: sum of 2 quarters · filed 2026-05-07 | $72.45M derived: sum of 3 quarters · filed 2026-05-07 | $97.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $24.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.36M derived: sum of 2 quarters · filed 2026-02-26 | $74.89M derived: sum of 3 quarters · filed 2026-08-06 | $100.25M 10-K · filed 2026-02-26 |
| 2025-09-30 | $25.30M 10-Q · filed 2025-11-06 | $50.83M derived: sum of 2 quarters · filed 2026-08-06 | $76.19M 10-Q · filed 2025-11-06 | $101.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.53M 10-Q · filed 2026-08-06 | $50.89M 10-Q · filed 2026-08-06 | $76.18M derived: sum of 3 quarters · filed 2026-08-06 | $101.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $25.36M 10-Q · filed 2026-05-07 | $50.66M derived: sum of 2 quarters · filed 2026-05-07 | $75.65M derived: sum of 3 quarters · filed 2026-05-07 | $100.86M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $25.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $50.29M derived: sum of 2 quarters · filed 2026-02-26 | $75.50M derived: sum of 3 quarters · filed 2026-02-26 | $103.48M 10-K · filed 2026-02-26 |
| 2024-09-30 | $24.99M 10-Q · filed 2025-11-06 | $50.20M derived: sum of 2 quarters · filed 2025-11-06 | $78.19M 10-Q · filed 2025-11-06 | $104.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $25.21M 10-Q · filed 2025-08-11 | $53.20M 10-Q · filed 2025-08-11 | $79.29M derived: sum of 3 quarters · filed 2026-02-26 | $106.87M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $27.99M 10-Q · filed 2025-05-06 | $54.08M derived: sum of 2 quarters · filed 2026-02-26 | $81.66M derived: sum of 3 quarters · filed 2026-02-26 | $108.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $26.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $53.67M derived: sum of 2 quarters · filed 2026-02-26 | $80.31M derived: sum of 3 quarters · filed 2026-02-26 | $108.40M 10-K · filed 2026-02-26 |
| 2023-09-30 | $27.58M 10-Q · filed 2024-11-06 | $54.22M derived: sum of 2 quarters · filed 2024-11-06 | $82.30M 10-Q · filed 2024-11-06 | $107.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $26.64M 10-Q · filed 2024-08-01 | $54.73M 10-Q · filed 2024-08-01 | $79.91M derived: sum of 3 quarters · filed 2025-02-27 | $104.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $28.08M 10-Q · filed 2024-05-07 | $53.27M derived: sum of 2 quarters · filed 2025-02-27 | $77.85M derived: sum of 3 quarters · filed 2025-02-27 | $101.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $25.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $49.77M derived: sum of 2 quarters · filed 2025-02-27 | $73.70M derived: sum of 3 quarters · filed 2025-02-27 | $99.85M 10-K · filed 2025-02-27 |
| 2022-09-30 | $24.58M 10-Q · filed 2023-11-07 | $48.52M derived: sum of 2 quarters · filed 2023-11-07 | $74.66M 10-Q · filed 2023-11-07 | $96.75M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $23.94M 10-Q · filed 2023-08-08 | $50.08M 10-Q · filed 2023-08-08 | $72.17M derived: sum of 3 quarters · filed 2024-02-28 | $93.16M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $26.14M 10-Q · filed 2023-05-08 | $48.23M derived: sum of 2 quarters · filed 2024-02-28 | $69.23M derived: sum of 3 quarters · filed 2024-02-28 | $90.36M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $22.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $43.08M derived: sum of 2 quarters · filed 2024-02-28 | $64.22M derived: sum of 3 quarters · filed 2024-02-28 | $85.25M 10-K · filed 2024-02-28 |
| 2021-09-30 | $21.00M 10-Q · filed 2022-11-03 | $42.13M derived: sum of 2 quarters · filed 2022-11-03 | $63.16M 10-Q · filed 2022-11-03 | $76.99M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $21.14M 10-Q · filed 2022-08-08 | $42.16M 10-Q · filed 2022-08-08 | $55.99M derived: sum of 3 quarters · filed 2023-02-27 | $69.25M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $21.03M 10-Q · filed 2022-05-05 | $34.86M derived: sum of 2 quarters · filed 2023-02-27 | $48.11M derived: sum of 3 quarters · filed 2023-02-27 | $60.59M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $13.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $27.08M derived: sum of 2 quarters · filed 2023-02-27 | $39.57M derived: sum of 3 quarters · filed 2023-02-27 | $50.35M 10-K · filed 2023-02-27 |
| 2020-09-30 | $13.25M 10-Q · filed 2021-11-04 | $25.74M derived: sum of 2 quarters · filed 2021-11-04 | $36.52M 10-Q · filed 2021-11-04 | $45.41M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $12.48M 10-Q · filed 2021-08-04 | $23.27M 10-Q · filed 2021-08-04 | $32.16M derived: sum of 3 quarters · filed 2022-02-28 | $41.06M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $10.79M 10-Q · filed 2021-05-05 | $19.67M derived: sum of 2 quarters · filed 2022-02-28 | $28.57M derived: sum of 3 quarters · filed 2022-02-28 | $42.29M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $8.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $17.79M derived: sum of 2 quarters · filed 2022-02-28 | $31.50M derived: sum of 3 quarters · filed 2022-02-28 | $38.38M 10-K · filed 2022-02-28 |
| 2019-09-30 | $8.90M 10-Q · filed 2020-11-05 | $22.61M derived: sum of 2 quarters · filed 2020-11-05 | $29.49M 10-Q · filed 2020-11-05 | $35.13M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $13.71M 10-Q · filed 2020-08-07 | $20.59M 10-Q · filed 2020-08-07 | $26.23M derived: sum of 3 quarters · filed 2021-02-26 | $31.74M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $6.87M 10-Q · filed 2020-05-07 | $12.52M derived: sum of 2 quarters · filed 2021-02-26 | $18.03M derived: sum of 3 quarters · filed 2021-02-26 | $22.74M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $11.16M derived: sum of 2 quarters · filed 2021-02-26 | $15.87M derived: sum of 3 quarters · filed 2021-02-26 | $18.79M 10-K · filed 2021-02-26 |
| 2018-09-30 | $5.51M 10-Q · filed 2019-11-06 | $10.22M derived: sum of 2 quarters · filed 2019-11-06 | $13.14M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $4.71M 10-Q · filed 2019-08-06 | $7.63M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $2.92M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $4.41M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $2.95M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |